MentionFox
Home › Layoffs › enGene Therapeutics Inc.
SEC filings · Form 8-K, Item 2.05

enGene Therapeutics Inc. layoffs and restructuring

Before you join, sell to or invest in enGene Therapeutics Inc.

MentionFox check on enGene Therapeutics Inc.: no red flags found in 4 sources; 1 item to note (checked 6 November 2026). mentionfox.com/c/layoffs/engene-therapeutics

  • Note: Layoff plan disclosed Jun 2026 (filing)

Check enGene Therapeutics Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about enGene Therapeutics Inc.?

Every exit or restructuring plan enGene Therapeutics Inc. reported on Form 8-K under Item 2.05: the filing's own words on employees affected, share of workforce, locations, charges and timing.

As of November 6, 2026, enGene Therapeutics Inc. has reported 2 exit or restructuring plans to the SEC on Form 8-K under Item 2.05, the latest filed on June 18, 2026. enGene Therapeutics Inc. trades on Nasdaq as ENGN; it was formerly enGene Holdings Inc. No WARN notice under its name is on file in the states covered here (Form 8-K, June 18, 2026).

Who owns enGene Holdings Inc.?

12 companies announced layoffs this week.

Companies cutting jobs this week. Before you unlock: the company, the number of employees and what is inside. After: every way we found to reach the company. No individual is named in a layoff.

Artiva Biotherapeutics, Inc.announced layoffs
Eos Energy Enterprises, Inc.announced layoffs
SOUNDHOUND AI, INC.announced layoffs
Portillo's Inc.announced layoffs
Acumen Pharmaceuticals, Inc.announced layoffs of about 52 employees
Check one company free

ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies ↓

Is this your company?

Owed money by them or selling to them? See the free Snapshot of enGene Therapeutics Inc.

Watch enGene Therapeutics Inc.: email me the next time it files something

Free to see. No signup.

SEC filings2
Latest filing2026-06-18

enGene Therapeutics Inc. reported 2 exit or restructuring plans on Form 8-K under Item 2.05. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.

Did enGene Therapeutics have layoffs in 2026? What its filings say

enGene Therapeutics Inc. (CIK 1980845) reported 2 exit or restructuring plans to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.

Form 8-K/A filed 2026-06-18

Expected charges

Subject to the applicable recipient remaining actively employed and in good standing with the Company, aggregate performance-based equity retention awards (inclusive of the Executive Performance Option, as defined below) will vest based upon the achievement of two milestones: (i) confirmation from the Food and Drug Administration (the "FDA") that the Company's filing of the Biologics License Application ("BLA") with the FDA with respect to detalimogene has been completed and accepted by the FDA, provided that such confirmation is received by the Company from the FDA no later than September 30, 2027 (the "BLA Milestone"), with approximately $1.4 million in non-cash stock-based compensation expense recognized upon vesting, and (ii) regulatory approval from the FDA with respect to detalimogene, provided that such regulatory approval is received by the Company from the FDA no later than December 31, 2028 (the "Approval Milestone" and together with the BLA Milestone, the "Milestones"), with approximately $1.4 million in non-cash stock-based compensation expense recognized upon vesting.

Open the filing

Form 8-K filed 2026-06-15

This filing reports Item 2.05, and its section states none of employees affected, share of workforce, locations, charges or timing in a single sentence. The full text is in the filing.

Open the filing

Also on the record for enGene Therapeutics Inc.

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G/A, by Deep Track Capital, LP—5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Perceptive Advisors LLC9.99% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P.—5%+ stakesSource
August 13, 2026Stake report, Schedule 13G/A, by Raymond Debbane9.3% of the class5%+ stakesSource
August 12, 2026Stake report, Schedule 13G/A, by Blue Owl Capital Holdings LP0.76% of the class5%+ stakesSource
July 22, 2026Stake report, Schedule 13G, by Anders Hove5% of the class5%+ stakesSource
July 16, 2026Leadership change: Richard Glickman departs, Director—Leadership changesSource
June 15, 2026Leadership change: Hussein Sweiti departs, Chief Medical Officer—Leadership changesSource
May 15, 2026Stake report, Schedule 13G/A, by Cormorant Asset Management, LP—5%+ stakesSource
May 14, 2026Stake report, Schedule 13G/A, by BML Investment Partners, L.P.9.95% of the class5%+ stakesSource
May 13, 2026Stake report, Schedule 13G, by BML Investment Partners, L.P.7.8% of the class5%+ stakesSource
May 5, 2026Stake report, Schedule 13G/A, by Raymond Debbane7.8% of the class5%+ stakesSource

Keep reading

More on enGene Therapeutics Inc. and the records around it.

enGene Therapeutics Inc. elsewhere on the record

Companies that share a holder

What do you want to do with enGene Therapeutics Inc.?

Want the whole picture on enGene Therapeutics Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on enGene Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on enGene Therapeutics Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 19 records.

RSS

Tools for this story

Each opens in a new tab, filled in for enGene Therapeutics Inc.. With no account yet, you sign up free and land on the result.

Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.

Where this comes from

Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.

A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey and Pennsylvania list a notice under the month it was posted or received, not the day, so their notices show a month. Tennessee gives the county rather than the city.

All recent layoffsThat week

Cite this page

Permanent URL: https://mentionfox.com/layoffs/engene-therapeutics
Last updated 2026-11-06
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
enGene Therapeutics Inc. layoffs and restructuring: 2 SEC filings (2026-06-18). MentionFox, 2026-11-06. https://mentionfox.com/layoffs/engene-therapeutics